Methods for treating systemic lupus erythematosus and other autoimmune conditions by using microRNA-31 compositions are disclosed. Methods of modifying interieukin-2 (IL-2) expression are also provided, comprising administering to a subject a composition that modifies microRNA-31 or RhoA expression.